Metabolic profile of chronic liver disease by NMR spectroscopy of human biopsies

International Journal of Molecular Medicine

Volumn 27, Issue 1, 2011, Pages 111-117

  Beatriz, Martínez Granados ^a   Morales, Jose Manuel ^a   Rodrigo, José Manuel ^b   Del Olmo, Juan ^b   Serra, Miguel Angel ^b   Ferrández, Antonio ^b   Celda, Bernardo ^a,c   Monleón, Daniel ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Chronic liver disease; HR MAS; Liver needle biopsy; Metabolic profiling; Metabolomics; NMR spectroscopy

Indexed keywords

AMINO ACID; FATTY ACID; GLUCOSE; PHOSPHOLIPID;

ADULT; AGED; ARTICLE; CHEMICAL ANALYSIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOMICS; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

ADULT; AGED; BIOPSY; CHRONIC DISEASE; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; MIDDLE AGED;

EID: 78651069387     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2010.563     Document Type: Article

References (48)

1. Guyton AC and Hall JE (eds.): Medical Physiology. Elsevier Saunders, Philadelphia, PA, 2006.
2. Ros PR and Mortele KJ: Diffuse liver disease. Clin Liver Dis 6: 181-201, 2002.
3. Simpson KJ and Finlayson ND: Clinical evaluation of liver disease. Baillieres Clin Gastroenterol 9: 639-659, 1995.
4. Friedman LS and Keeffe B (eds.): Handbook of liver disease. Churchill Livingstone, London, 2004.
5. Hunt N and Fleming K: Reproducibility of liver biopsy grading and staging. Liver 19: 169-170, 1999.
6. Brunt EM: Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 31: 241-246, 2000.
7. Ishak K, Baptista A, Bianchi L, et al: Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699, 1995.
8. Friedman SL: Liver fibrosis - from bench to bedside. J Hepatol 38 (Suppl 1): S38-S53, 2003.
9. Pinzani M, Rombouts K and Colagrande S: Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42: S22-S36, 2005.
10. Dezortova M, Taimr P, Skoch A, Spicak J and Hajek M: Etiology and functional status of liver cirrhosis by 31P MR spectroscopy. World J Gastroenterol 11: 6926-6931, 2005.
11. Kuriyama S, Yokoyama F, Inoue H, et al: Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factor-beta1 in hepatofibrogenesis of a rat cirrhosis model. Int J Mol Med 19: 317-324, 2007.
12. Canbay A, Friedman S and Gores GJ: Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39: 273-278, 2004.
13. Ramadori G and Saile B: Inflammation, damage repair, immune cells, and liver fibrosis: specific or nonspecific, this is the question. Gastroenterology 127: 997-1000, 2004. (Pubitemid 39208434)
14. Poli G: Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 21: 49-98, 2000.
15. Gutierrez-Reyes G, Gutierrez-Ruiz MC and Kershenobich D: Liver fibrosis and chronic viral hepatitis. Arch Med Res 38: 644-651, 2007.
16. Kaji K, Yoshiji H, Kitade M, et al: Impact of insulin resistance on the progression of chronic liver diseases. Int J Mol Med 22: 801-808, 2008.
17. Naveau S, Raynard B, Ratziu V, et al: Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 3: 167-174, 2005.
18. Ratziu V, Giral P, Munteanu M, et al: Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 25: 207-218, 2007.
19. Salcedo X, Medina J, Sanz-Cameno P, Garcia-Buey L, Martin-Vilchez S and Moreno-Otero R: Review article: angiogenesis soluble factors as liver disease markers. Aliment Pharmacol Ther 22: 23-30, 2005. (Pubitemid 40943871)
20. Parola M, Robino G and Dianzani MU: 4-hydroxy-2,3-alkenals as molecular mediators of oxidative stress in the pathogenesis of liver fibrosis (review). Int J Mol Med 4: 425-432, 1999.
21. Cobbold JF, Patel JH, Goldin RD, et al: Hepatic lipid profiling in chronic hepatitis C: An in vitro and in vivo proton magnetic resonance spectroscopy study. J Hepatol 52: 16-24, 2010.
22. Fischbach F and Bruhn H: Assessment of in vivo 1H magnetic resonance spectroscopy in the liver: a review. Liver Int 28: 297-307, 2008.
23. Sijens PE, Edens MA, Bakker SJ and Stolk RP: MRI-determined fat content of human liver, pancreas and kidney. World J Gastroenterol 16: 1993-1998, 2010.
24. Springer F, Machann J, Claussen CD, Schick F and Schwenzer NF: Liver fat content determined by magnetic resonance imaging and spectroscopy. World J Gastroenterol 16: 1560-1566, 2010.
25. Cheng LL, Ma MJ, Becerra L, et al: Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 94: 6408-6413, 1997. (Pubitemid 27270698)
26. Sitter B, Bathen TF, Singstad TE, et al: Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed: January 25, 2010 (Epub ahead of print).
27. Martinez-Bisbal MC, Monleon D, Assemat O, et al: Determination of metabolite concentrations in human brain tumour biopsy samples using HR-MAS and ERETIC measurements. NMR Biomed 22: 199-206, 2009.
28. Martinez-Granados B, Monleon D, Martinez-Bisbal MC, et al: Metabolite identification in human liver needle biopsies by high-resolution magic angle spinning 1H NMR spectroscopy. NMR Biomed 19: 90-100, 2006.
29. Monleon D, Morales JM, Gonzalez-Darder J, et al: Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J Proteome Res 7: 2882-2888, 2008.
30. Griffin JL, Bollard M, Nicholson JK and Bhakoo K: Spectral profiles of cultured neuronal and glial cells derived from HRMAS (1)H NMR spectroscopy. NMR Biomed 15: 375-384, 2002.
31. Hong YS, Coen M, Rhode CM, et al: Chemical shift calibration of 1H MAS NMR liver tissue spectra exemplified using a study of glycine protection of galactosamine toxicity. Magn Reson Chem 47 (Suppl 1): S47-S53, 2009.
32. Swanson MG, Zektzer AS, Tabatabai ZL, et al: Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med 55: 1257-1264, 2006.
33. Weybright P, Millis K, Campbell N, Cory DG and Singer S: Gradient, high-resolution, magic angle spinning 1H nuclear magnetic resonance spectroscopy of intact cells. Magn Reson Med 39: 337-345, 1998.
34. Cheng LL, Chang IW, Louis DN and Gonzalez RG: Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res 58: 1825-1832, 1998.
35. Maxwell RJ, Martinez-Perez I, Cerdan S, et al: Pattern recognition analysis of 1H NMR spectra from perchloric acid extracts of human brain tumor biopsies. Magn Reson Med 39: 869-877, 1998.
36. Duarte IF, Stanley EG, Holmes E, et al: Metabolic assessment of human liver transplants from biopsy samples at the donor and recipient stages using high-resolution magic angle spinning 1H NMR spectroscopy. Anal Chem 77: 5570-5578, 2005.
37. Cox IJ, Sharif A, Cobbold JF, Thomas HC and Taylor-Robinson SD: Current and future applications of in vitro magnetic resonance spectroscopy in hepatobiliary disease. World J Gastroenterol 12: 4773-4783, 2006.
38. Martinez-Bisbal MC, Marti-Bonmati L, Piquer J, et al: 1H and 13C HR-MAS spectroscopy of intact biopsy samples ex vivo and in vivo 1H MRS study of human high grade gliomas. NMR Biomed 17: 191-205, 2004.
39. Ludwig J, Batts KP, Moyer TP and Poterucha JJ: Advances in liver biopsy diagnosis. Mayo Clin Proc 69: 677-678, 1994.
40. Waters NJ, Garrod S, Farrant RD, et al.: High-resolution magic angle spinning (1)H NMR spectroscopy of intact liver and kidney: optimization of sample preparation procedures and biochemical stability of tissue during spectral acquisition. Anal Biochem 282: 16-23, 2000. (Pubitemid 30409419)
41. Piotto M, Elbayed K, Wieruszeski JM and Lippens G: Practical aspects of shimming a high resolution magic angle spinning probe. J Magn Reson 173: 84-89, 2005. (Pubitemid 40206420)
42. Schlemmer HP, Sawatzki T, Sammet S, et al: Hepatic phospholipids in alcoholic liver disease assessed by protonde-coupled 31P magnetic resonance spectroscopy. J Hepatol 42: 752-759, 2005. (Pubitemid 40501693)
43. Tarachiwin L, Ute K, Kobayashi A and Fukusaki E: 1H NMR based metabolic profiling in the evaluation of Japanese green tea quality. J Agric Food Chem 55: 9330-9336, 2007.
44. Sundler R and Akesson B: Regulation of phospholipid biosynthesis in isolated rat hepatocytes. Effect of different substrates. J Biol Chem 250: 3359-3367, 1975.
45. Mato JM and Ortiz P: Metabolism of methionine in liver disease. Methods Find Exp Clin Pharmacol 18 (Suppl B): 35-46, 1996.
46. Constantinou MA, Tsantili-Kakoulidou A, Andreadou I, Iliodromitis EK, Kremastinos DT and Mikros E: Application of NMR-based metabonomics in the investigation of myocardial ischemia-reperfusion, ischemic preconditioning and antioxidant intervention in rabbits. Eur J Pharm Sci 30: 303-314, 2007.
47. Waters NJ, Waterfield CJ, Farrant RD, Holmes E and Nicholson JK: Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity. Chem Res Toxicol 18: 639-654, 2005. (Pubitemid 40563278)
48. Rodrigo R, Cauli O, Gomez-Pinedo U, et al: Hyperammonemia Induces Neuroinflammation that Contributes to Cognitive Impairment in Rats with Hepatic Encephalopathy. Gastroenterology 139: 675-684, 2010.